Zura Bio Limited Class A Ordinary Shares (ZURA) Stock Price

ZURAStock
$6.32+213.43%52W
Market Cap$605.64M
P/E
PEG Ratio
Div yield
Beta-0.06

ZURA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-9.80%
Price vs S&P 500 (4W)10.67%
VGM Score83.00

ZURA Earnings Surprise History

Q2 25-0.17est. -0.18
Q3 25-0.21est. -0.18
Q4 25-0.49est. -0.15
Q1 26-0.22est. -0.18
Q2 26-0.21est. -0.19

ZURA Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.36
4.36
4.36
4.43

Industry Peers — Biological Products(183)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
ZURAZura Bio Limited Class A Ordinary Shares
A$6.32
AMGNAmgen IncCCB$442.24
GILDGilead Sciences IncCBB$148.77
MRNAModerna, Inc. Common StockDCA$158.83
ARGXargenx SE American Depositary SharesDAB$1019.49
RVMDRevolution Medicines, Inc. Common StockFA$211.38
BIIBBiogen Inc. Common StockCDB$220.77
BNTXBioNTech SE American Depositary ShareCCB$114.05
NBIXNeurocrine Biosciences IncCBC$153.37
EXELExelixis IncCBB$56.72
HALOHalozyme Therapeutics, Inc.CBA$109.32

About Zura Bio Limited Class A Ordinary Shares

Zura Bio Ltd is a clinical-stage immunology company developing novel dual-pathway antibodies to treat autoimmune and inflammatory diseases. The company has three lead programs that have completed Phase I/Ib studies and are advancing to Phase II trials. Its pipeline includes tibulizumab and torudokimab, which are being evaluated for efficacy, safety, and dosing convenience across multiple therapeutic indications.